Published in J Virol on July 01, 2006
Extreme genetic fragility of the HIV-1 capsid. PLoS Pathog (2013) 1.35
Antiretroviral drug resistance in HIV-2: three amino acid changes are sufficient for classwide nucleoside analogue resistance. J Infect Dis (2009) 1.06
Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro. Antimicrob Agents Chemother (2007) 1.05
Human telomerase model shows the role of the TEN domain in advancing the double helix for the next polymerization step. Proc Natl Acad Sci U S A (2011) 0.92
Conformational States of HIV-1 Reverse Transcriptase for Nucleotide Incorporation vs Pyrophosphorolysis-Binding of Foscarnet. ACS Chem Biol (2016) 0.85
High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol (1987) 43.61
Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci U S A (1993) 22.33
Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science (1998) 11.23
Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J (1989) 10.84
Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc Natl Acad Sci U S A (1993) 9.47
Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science (1991) 8.76
High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. Science (1989) 8.73
Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A (1993) 6.14
Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother (1993) 5.08
Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science (1995) 4.98
Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity. Proc Natl Acad Sci U S A (1989) 4.15
HIV-1 reverse transcription. A termination step at the center of the genome. J Mol Biol (1994) 4.15
Structure of the RNA-dependent RNA polymerase of poliovirus. Structure (1997) 3.88
A single residue in DNA polymerases of the Escherichia coli DNA polymerase I family is critical for distinguishing between deoxy- and dideoxyribonucleotides. Proc Natl Acad Sci U S A (1995) 3.78
A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol Cell (1999) 3.67
Related functional domains in virus DNA polymerases. EMBO J (1987) 3.35
Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol (1996) 3.21
Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 A resolution. J Mol Biol (1998) 3.14
3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother (1992) 2.97
In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther (1999) 2.85
Rift Valley fever virus L segment: correction of the sequence and possible functional role of newly identified regions conserved in RNA-dependent polymerases. J Gen Virol (1994) 2.84
Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1. Antimicrob Agents Chemother (2004) 2.44
Identification of amino acids in herpes simplex virus DNA polymerase involved in substrate and drug recognition. Proc Natl Acad Sci U S A (1988) 2.27
Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS (2003) 1.78
A structural and primary sequence comparison of the viral RNA-dependent RNA polymerases. Nucleic Acids Res (2003) 1.77
Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance. J Infect Dis (1998) 1.75
World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS (2001) 1.73
How E. coli DNA polymerase I (Klenow fragment) distinguishes between deoxy- and dideoxynucleotides. J Mol Biol (1998) 1.72
The Nef protein of human immunodeficiency virus type 1 enhances serine phosphorylation of the viral matrix. J Virol (1997) 1.52
Functional analysis of amino acid residues constituting the dNTP binding pocket of HIV-1 reverse transcriptase. J Biol Chem (1998) 1.51
Retroviral mutation rates and reverse transcriptase fidelity. Front Biosci (2003) 1.48
Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates. Antimicrob Agents Chemother (1995) 1.39
A single-base change within the DNA polymerase locus of herpes simplex virus type 2 can confer resistance to aphidicolin. J Virol (1987) 1.39
Replication defect of moloney murine leukemia virus with a mutant reverse transcriptase that can incorporate ribonucleotides and deoxyribonucleotides. J Virol (1998) 1.33
Molecular basis of fidelity of DNA synthesis and nucleotide specificity of retroviral reverse transcriptases. Prog Nucleic Acid Res Mol Biol (2002) 1.32
Structural determinants in human DNA polymerase gamma account for mitochondrial toxicity from nucleoside analogs. J Mol Biol (2003) 1.29
Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo. J Infect Dis (1997) 1.23
Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet. J Virol (1996) 1.18
Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design. Nucleic Acids Res (2003) 1.18
A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT. AIDS (2005) 1.17
Nucleoside and nucleotide inhibitors of HIV-1 replication. Cell Mol Life Sci (2006) 1.16
Alkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside-resistant human immunodeficiency virus type 1 and select for resistance mutations that suppress zidovudine resistance. Antimicrob Agents Chemother (2001) 1.16
In vitro hypersusceptibility of human immunodeficiency virus type 1 subtype C protease to lopinavir. Antimicrob Agents Chemother (2003) 1.14
Mechanistic understanding of an altered fidelity simian immunodeficiency virus reverse transcriptase mutation, V148I, identified in a pig-tailed macaque. J Biol Chem (2003) 1.13
The molecular mechanism of multidrug resistance by the Q151M human immunodeficiency virus type 1 reverse transcriptase and its suppression using alpha-boranophosphate nucleotide analogues. J Biol Chem (2002) 1.09
Drug resistance patterns of recombinant herpes simplex virus DNA polymerase mutants generated with a set of overlapping cosmids and plasmids. J Virol (2003) 1.08
The impact of multidideoxynucleoside resistance-conferring mutations in human immunodeficiency virus type 1 reverse transcriptase on polymerase fidelity and error specificity. J Virol (1998) 1.08
Phenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with human immunodeficiency virus type 1. J Virol (2005) 1.05
Molecular architecture of the mutagenic active site of human immunodeficiency virus type 1 reverse transcriptase: roles of the beta 8-alpha E loop in fidelity, processivity, and substrate interactions. Biochemistry (2000) 1.04
Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine. J Infect Dis (2001) 1.03
Second-site reversion of a human immunodeficiency virus type 1 reverse transcriptase mutant that restores enzyme function and replication capacity. J Virol (1999) 1.03
Role of glutamine 151 of human immunodeficiency virus type-1 reverse transcriptase in substrate selection as assessed by site-directed mutagenesis. Biochemistry (2000) 1.02
Characterisation of foscarnet-resistant strains of human immunodeficiency virus type 1. Virology (1995) 1.01
Mechanism by which phosphonoformic acid resistance mutations restore 3'-azido-3'-deoxythymidine (AZT) sensitivity to AZT-resistant HIV-1 reverse transcriptase. J Biol Chem (2000) 0.99
A zidovudine-resistant simian immunodeficiency virus mutant with a Q151M mutation in reverse transcriptase causes AIDS in newborn macaques. Antimicrob Agents Chemother (1997) 0.94
Mutational analysis of Phe160 within the "palm" subdomain of human immunodeficiency virus type 1 reverse transcriptase. J Mol Biol (1999) 0.94
Genetic basis of hypersusceptibility to protease inhibitors and low replicative capacity of human immunodeficiency virus type 1 strains in primary infection. J Virol (2004) 0.93
Inhibition of HIV-1 reverse transcription: basic principles of drug action and resistance. Expert Rev Anti Infect Ther (2004) 0.92
Purifying selection masks the mutational flexibility of HIV-1 reverse transcriptase. J Biol Chem (2004) 0.91
Evidence of stavudine-related phenotypic resistance among zidovudine-pretreated HIV-1-infected subjects receiving a therapeutic regimen of stavudine plus lamivudine. J Acquir Immune Defic Syndr (1999) 0.90
Distinct function of conserved amino acids in the fingers of Saccharomyces cerevisiae DNA polymerase alpha. J Biol Chem (2003) 0.88
A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-beta-2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother (1999) 0.84
Aphidicolin resistance in herpes simplex virus type 1 appears to alter substrate specificity in the DNA polymerase. J Virol (1989) 0.83
Substitution of conserved hydrophobic residues in motifs B and C of HIV-1 RT alters the geometry of its catalytic pocket. Biochemistry (2002) 0.83
Site-specific incorporation of nucleoside analogs by HIV-1 reverse transcriptase and the template grip mutant P157S. Template interactions influence substrate recognition at the polymerase active site. J Biol Chem (2000) 0.83
Characterization of the DNA polymerase gene of varicella-zoster viruses resistant to acyclovir. J Gen Virol (2001) 0.81
Aphidicolin-resistant DNA polymerase of bacteriophage phi 29 APHr71 mutant is hypersensitive to phosphonoacetic acid and butylphenyldeoxyguanosine 5'-triphosphate. Virology (1990) 0.81
Role of Q190 of MuLV RT in ddNTP resistance and fidelity of DNA synthesis: a molecular model of interactions with substrates. Protein Eng (2000) 0.80
A positively charged side chain at position 154 on the beta8-alphaE loop of HIV-1 RT is required for stable ternary complex formation. Nucleic Acids Res (2003) 0.79
Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc Natl Acad Sci U S A (2006) 6.82
DNA polymerase epsilon and delta proofreading suppress discrete mutator and cancer phenotypes in mice. Proc Natl Acad Sci U S A (2009) 2.57
Human immunodeficiency virus type 1 recombination: rate, fidelity, and putative hot spots. J Virol (2002) 2.50
High incidence of epithelial cancers in mice deficient for DNA polymerase delta proofreading. Proc Natl Acad Sci U S A (2002) 1.95
Mutator phenotypes caused by substitution at a conserved motif A residue in eukaryotic DNA polymerase delta. J Biol Chem (2005) 1.94
Mutation at the polymerase active site of mouse DNA polymerase delta increases genomic instability and accelerates tumorigenesis. Mol Cell Biol (2007) 1.74
Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa. Clin Infect Dis (2009) 1.33
Lethal mutagenesis of HIV. Virus Res (2005) 1.26
Defects in homologous recombination repair in mismatch-repair-deficient tumour cell lines. Hum Mol Genet (2002) 1.19
Incorporation of uracil into minus strand DNA affects the specificity of plus strand synthesis initiation during lentiviral reverse transcription. J Biol Chem (2002) 1.16
Decoding cell lineage from acquired mutations using arbitrary deep sequencing. Nat Methods (2011) 1.12
Mutational analysis of HIV-1 long terminal repeats to explore the relative contribution of reverse transcriptase and RNA polymerase II to viral mutagenesis. J Biol Chem (2002) 1.09
Antiretroviral drug resistance in HIV-2: three amino acid changes are sufficient for classwide nucleoside analogue resistance. J Infect Dis (2009) 1.06
Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro. Antimicrob Agents Chemother (2007) 1.05
Mutator suppression and escape from replication error-induced extinction in yeast. PLoS Genet (2011) 1.05
DNA replication error-induced extinction of diploid yeast. Genetics (2014) 0.95
DNA replication fidelity: proofreading in trans. Curr Biol (2006) 0.92
Purifying selection masks the mutational flexibility of HIV-1 reverse transcriptase. J Biol Chem (2004) 0.91
Antimutator variants of DNA polymerases. Crit Rev Biochem Mol Biol (2011) 0.88
Emergence of DNA polymerase ε antimutators that escape error-induced extinction in yeast. Genetics (2013) 0.87
Structural determinants of slippage-mediated mutations by human immunodeficiency virus type 1 reverse transcriptase. J Biol Chem (2006) 0.87
Use of somatic mutations to quantify random contributions to mouse development. BMC Genomics (2013) 0.87
A random mutation capture assay to detect genomic point mutations in mouse tissue. Nucleic Acids Res (2011) 0.86
Case series: acute tumor lysis syndrome in mutator mice with disseminated lymphoblastic lymphoma. Toxicol Pathol (2010) 0.84
Expression of a human cytochrome p450 in yeast permits analysis of pathways for response to and repair of aflatoxin-induced DNA damage. Mol Cell Biol (2005) 0.84
Divergent cellular phenotypes of human and mouse cells lacking the Werner syndrome RecQ helicase. DNA Repair (Amst) (2009) 0.83
DNA polymerase delta-dependent repair of DNA single strand breaks containing 3'-end proximal lesions. Nucleic Acids Res (2007) 0.83
Ig gene somatic hypermutation in mice defective for DNA polymerase delta proofreading. Int Immunol (2003) 0.81
Tumor necrosis factor, tumor necrosis factor inhibition, and cancer risk. Curr Med Res Opin (2015) 0.81
Chimeric human immunodeficiency virus type 1 and feline immunodeficiency virus reverse transcriptases: role of the subunits in resistance/sensitivity to non-nucleoside reverse transcriptase inhibitors. Mol Pharmacol (2002) 0.77